Medicxi bankrolls the launch of a pair of biotech twins focused on orexins for narcolepsy and more
The venture investors at Medicxi are funding a pair of biotech spinouts from UK-based Sosei Heptares, which has been fine tuning its expertise in G protein-coupled receptors for a number of years now.
Medicxi is offering €40 million to kickstart two new companies — the twins Orexia and Inexia, which will target Orexin OX1 and OX2 for neurological diseases. The Heptares subsidiary will put its researchers to work on the two projects, identifying narcolepsy as one key disease on the menu.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters